Atlas Trials

Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma

Clinical trial NCT05057845 · RECRUITING

Trial details

NCT number
NCT05057845
Sponsor
Fudan University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Advanced Hepatocellular Carcinoma
Start date
2021-09-26
Primary completion
2026-09-20
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.